Korro Bio (KRRO)
NASDAQ:KRRO
Want to see KRRO full AI Analyst Report?
Top Page
Korro Bio
(NASDAQ:KRRO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$10.00
▼(-30.51% Downside)
Action:Reiterated
Date:05/19/26
The score is held down primarily by weak financial performance (large losses and significant cash burn alongside declining/volatile revenue) and a bearish technical setup (price below major moving averages with negative MACD). Offsetting factors include constructive corporate events (PIPE financing and pipeline advancement), but valuation support is limited given ongoing losses and no dividend data.
Positive Factors
Strong preclinical data for KRRO-111
Robust >90% editing and ~90% functional protein restoration in PiZZ mice indicates the platform can deliver high on‑target efficacy in vivo. Such best‑in‑class preclinical validation materially raises the odds of clinical success, strengthens IP and partner interest, and supports durable program value beyond short‑term noise.
Negative Factors
High cash burn and negative free cash flow
Sustained annual cash burn near $70M substantially increases reliance on external financing. Over a multi‑quarter horizon this raises dilution risk and can force tradeoffs between programs or slower development pacing if capital markets sour, making long‑term execution contingent on continued successful raises or partnership monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong preclinical data for KRRO-111
Robust >90% editing and ~90% functional protein restoration in PiZZ mice indicates the platform can deliver high on‑target efficacy in vivo. Such best‑in‑class preclinical validation materially raises the odds of clinical success, strengthens IP and partner interest, and supports durable program value beyond short‑term noise.
Read all positive factors
Korro Bio (KRRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$144.37M
Dividend YieldN/A
Average Volume (3M)734.66K
Price to Earnings (P/E)―
Beta (1Y)2.65
Revenue Growth-20.31%
EPS Growth-23.75%
CountryUS
Employees112
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-11.68
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue24.12
Enterprise Value/Gross Profit32.94
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$19.70Price Target Upside36.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.16
Revenue Forecast (FY)$2.10M
Korro Bio Business Overview & Revenue Model
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts....
How the Company Makes Money
Korro Bio generates revenue primarily through research collaborations, licensing agreements, and upfront payments from strategic partnerships with pharmaceutical companies. These agreements often include milestone-based payments tied to the progre...
Korro Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.84M | 6.39M | 2.27M | 0.00 | 0.00 | 14.07M |
| Gross Profit | 2.81M | 2.11M | 2.27M | 0.00 | 0.00 | 10.23M |
| EBITDA | -78.15M | -83.06M | -88.34M | -80.90M | -56.49M | -80.07M |
| Net Income | -113.50M | -117.26M | -83.58M | -81.17M | -58.03M | -84.69M |
Balance Sheet | ||||||
| Total Assets | 183.62M | 113.51M | 226.24M | 221.66M | 73.74M | 185.36M |
| Cash, Cash Equivalents and Short-Term Investments | 113.97M | 75.16M | 126.09M | 166.15M | 55.85M | 130.71M |
| Total Debt | 42.88M | 43.49M | 44.77M | 33.21M | 166.99M | 45.60M |
| Total Liabilities | 63.99M | 62.07M | 65.83M | 51.75M | 172.77M | 54.53M |
| Stockholders Equity | 119.63M | 51.44M | 160.41M | 169.91M | -99.03M | 130.82M |
Cash Flow | ||||||
| Free Cash Flow | -70.60M | -79.08M | -77.98M | -75.12M | -58.86M | -36.54M |
| Operating Cash Flow | -70.18M | -78.56M | -60.07M | -67.28M | -53.65M | -32.09M |
| Investing Cash Flow | -21.03M | 43.99M | -123.35M | 11.16M | 11.06M | -39.50M |
| Financing Cash Flow | 88.72M | 685.00K | 69.36M | 187.76M | 18.00K | 115.94M |
Korro Bio Technical Analysis
Negative
14.39
Price Trends
12.28
Negative
11.51
Negative
18.44
Negative
Market Momentum
-0.71
Positive
46.07
Neutral
27.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Negative. The current price of 14.39 is above the 20-day moving average (MA) of 11.88, above the 50-day MA of 12.28, and below the 200-day MA of 18.44, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 46.07 is Neutral, neither overbought nor oversold. The STOCH value of 27.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRRO.
Korro Bio Risk Analysis
Korro Bio disclosed 85 risk factors in its most recent earnings report. Korro Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Korro Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $693.27M | -9.27 | -33.07% | ― | ― | -20.34% | |
52 Neutral | $417.34M | -12.91 | -4.21% | ― | 121.11% | 80.74% | |
52 Neutral | $772.30M | -3.35 | -78.12% | ― | ― | 7.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $442.78M | -2.30 | -36.83% | ― | 383560.87% | 20.87% | |
49 Neutral | $144.37M | -1.67 | -117.86% | ― | -20.31% | -23.75% | |
47 Neutral | $825.77M | -6.09 | -101.19% | ― | ― | -3.74% |
* Healthcare Sector Average
KRRO
Korro Bio
11.20
-3.61
-24.38%
ASMB
Assembly Biosciences
26.50
12.94
95.43%
ANNX
Annexon Biosciences
5.44
3.38
164.08%
FDMT
4D Molecular Therapeutics
8.69
5.09
141.39%
DSGN
Design Therapeutics
11.01
7.14
184.50%
AURA
Aura Biosciences Inc
7.65
1.71
28.79%
Korro Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency
Positive
May 19, 2026
On May 19, 2026, Korro Bio announced it has selected KRRO-111, a GalNAc-conjugated oligonucleotide delivered subcutaneously to liver cells, as a development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency, adding the progra...
Business Operations and StrategyPrivate Placements and Financing
Korro Bio Announces Oversubscribed $85M PIPE Financing
Positive
Mar 9, 2026
On March 9, 2026, Korro Bio entered into a subscription agreement for an oversubscribed private investment in public equity, selling common shares and pre-funded warrants to institutional investors for expected gross proceeds of about $85 million,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.